Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on ...

US regulators grant full approval to Novavax shot but sharply limit eligibility. New studies on heart risks required, raising ...

But we're working with the FDA. We plan on partnering with them ... And this isn't specific to Novavax, just in general. Are the authorities saying, hey, well, there needs to be a full-blown ...

The FDA is a massive agency charged with regulating ... Earlier this year, the Trump administration sought for drug manufacturer Novavax to commit to conducting a new clinical trial on its ...

People “don’t like the uncertainties,” he says. Most notable, the FDA did not approve Novavax’s peptide vaccine for SARS-CoV-2, which Makary has insisted must be tested again for efficacy.

Califf also expressed concern over reports that political appointees halted the full approval of Novavax’s Covid-19 vaccine, saying that FDA scientists should be shielded from any political ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the ...

The FDA delayed full approval in April. On Thursday, Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343 ...

Novavax also said it is in discussions with the Food and Drug Administration about full approval for its Covid-19 vaccine, Nuvaxovid, which has only the emergency approval it received in the pandemic.